Dickinson brings nearly 20 years’ industry experience to the role and will build on Quantum’s position as a leading specials supplier in the UK. His career has spanned chromatography research with ICI, quality assurance at Cussons International, management at 3M Healthcare and a role developing pharmaceutical, healthcare and beauty products in Africa. Latterly, he was head of quality and compliance at Perrigo (formerly Galpharm).
Quantum Pharmaceutical is a pharmaceutical specials manufacturer licensed by the UK MHRA to supply pharmacies, chemists, dispensing doctors and hospitals with bespoke medicines.
Quantum Pharmaceutical appoints quality director
Brings 20 years’ experience to the role
You may also like
Manufacturing
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Portable gas detection in the pharmaceutical sector
Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
New legal duties for QPs in decentralised manufacturing
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Manufacturing
FDA escalates action against Dabur India over systemic data-integrity and cGMP failures
The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies